Biotech · Private company · Watertown, MA, US
iTeos Therapeutics, Inc.
SEC CIK 0001808865
Track this companyFree. Adds iTeos Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials85 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- CarboplatinPhase 2 · Metastatic NSCLC - Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- inupadenantPhase 2 · Metastatic NSCLC - Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- PemetrexedPhase 2 · Metastatic NSCLC - Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
- ChemotherapyPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- DexamethasonePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- EOS100850Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- EOS884448Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- IberdomidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)PHASE3 · ACTIVE_NOT_RECRUITING · started Jun 10, 2024ClinicalTrials.gov NCT06472076 · fetched Nov 12, 2026
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 14, 2023ClinicalTrials.gov NCT06062420 · fetched Nov 12, 2026
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Oct 14, 2022ClinicalTrials.gov NCT05565378 · fetched Nov 12, 2026
- Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Aug 26, 2022ClinicalTrials.gov NCT05403385 · fetched Nov 12, 2026
- Study of Novel Regimens in Relapsed or Refractory Multiple MyelomaPHASE1 · TERMINATED · started May 1, 2022ClinicalTrials.gov NCT05289492 · fetched Nov 12, 2026
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsPHASE1_PHASE2 · UNKNOWN · started Sep 6, 2021ClinicalTrials.gov NCT05060432 · fetched Nov 12, 2026
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Jun 25, 2020ClinicalTrials.gov NCT04446351 · fetched Nov 12, 2026
- First-in-Human Study of EOS100850 (Inupadenant) in Patients with CancerPHASE1 · COMPLETED · started Feb 5, 2019ClinicalTrials.gov NCT03873883 · fetched Nov 12, 2026
SEC filings10
- 8-K · 8-KSEC EDGAR · filed Aug 29, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 21, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 17, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 5, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 28, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 13, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Apr 28, 2025 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 5, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jan 13, 2025 · fetched Nov 12, 2026